The making and unmaking of stem-like, aggressive breast cancer cells

August 9, 2012

Breast cancers that depend on the hormones estrogen and progesterone are susceptible to treatments targeting these hormones. Take away this dependence and you lose a valuable treatment option.

A University of Colorado Cancer Center study published as a featured article in the journal Oncogene shows how does just this – by suppressing a key microRNA, progestins return cells to a stem-cell-like state in which they haven't yet differentiated, and are thus more resistant to chemotherapies and more likely to carry a poor prognosis.

"The reason we were looking into the possible role of microRNAs in the dedifferentiation of breast into this aggressive, chemo-resistant phenotype is that microRNAs tend to be good, druggable targets. Because one microRNA may regulate many genes involved in a cancerous signaling pathway, we hoped to find one target with many beneficial effects," says Diana Cittelly, PhD, postdoctoral fellow at the CU Cancer Center and the paper's first author. The study was a collaboration between the CU Cancer Center labs of Jennifer Richer, PhD, and Carol Sartorius, PhD.

Specifically, the study shows that progestins regulate miRNA-29 – a molecule that helps to decide which of a cell's genes are and are not turned into proteins. This regulation of miRNA-29 creates a cascade that stimulates breast cancer cells to revert back to a stem-like state, marked by proteins CD44 and CK5. In animal models, these stem-like cells helped breast cancer evolve around the blockages of current treatments..

"We can manipulate this miRNA-29 in cell lines," Cittelly says, "and we hope technology isn't too far in the future that will allow us to deliver miRNA-29 in human cancers as well."

Turn off the role of miRNA-29 and the hope is that breast cancers won't be able to gain stem cell-like traits and lose their dependence.

Explore further: Heterogeneous ER+ breast cancer models allow more accurate drug testing

Related Stories

Heterogeneous ER+ breast cancer models allow more accurate drug testing

August 6, 2012
(Medical Xpress) -- Cell cultures are homogeneous. Human tumors are not. A University of Colorado Cancer Center study recently published in the journal Breast Cancer Research and Treatment reports the development of human-derived ...

New target, new drug in breast cancer

June 4, 2012
Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.